“…The increasing use of advanced devices for diabetes treatment, such as continuous subcutaneous insulin infusion, flash glucose monitoring, continuous glucose monitoring systems, and sensor‐augmented pumps, has resulted in important improvements in disease management, especially in terms of prevention of hypoglycaemic events and minimizing intraday glycaemic variability. However, some recent reports have described ACD caused by components contained in the adhesive tapes used to attach these devices to the skin of patients with diabetes . Cutaneous symptoms could be related to a worsening of glycaemic control, and therefore necessitate a change in insulin administration method(s), with a switch to more invasive multiple injection therapy.…”